Amgen France, Value Access and Policy, Paris, France.
Kantar Health, Paris, France.
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e13-e28. doi: 10.1016/j.clml.2018.08.019. Epub 2018 Sep 5.
New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM.
This observational, cross-sectional, multicenter study enrolled patients (≥ 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016. HRQoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) and the Quality of Life Multiple Myeloma module (QLQ-MY20).
In total, 445 patients were included in the study; 402 (90%) completed the EORTC QLQ-C30 and QLQ-MY20 questionnaires. HRQoL decreased significantly with treatment line. Patients in the first treatment-free interval had relatively high scores. At later lines, patients receiving active treatment had better scores than those whose treatment had ended. High EORTC QLQ-C30 global health status scores were associated with good treatment response, few adverse events, and long duration of treatment, and were strongly influenced by the Eastern Cooperative Oncology Group performance status. Global health status scores correlated well with the 4 items of the QLQ-MY20 (future perspective, 0.46; body image, 0.41; disease symptoms, -0.57; side effects of treatment, -0.53).
Effective treatment options in MM can help maintain HRQoL by influencing treatment response levels and delaying disease progression.
多发性骨髓瘤（MM）的新疗法提高了患者的预期寿命，但缺乏真实世界中 MM 患者的健康相关生活质量（HRQoL）数据。本研究在法国进行，旨在探讨 MM 患者的治疗结局与 HRQoL 之间的关系。
这是一项观察性、横断面、多中心研究，纳入了 2016 年 2 月至 3 月期间至少咨询过一次医生的有症状 MM 患者（≥ 18 岁）。使用欧洲癌症研究与治疗组织（EORTC）核心生活质量问卷（QLQ-C30）和生活质量多发性骨髓瘤模块（QLQ-MY20）评估 HRQoL。
共有 445 例患者纳入本研究，其中 402 例（90%）完成了 EORTC QLQ-C30 和 QLQ-MY20 问卷。随着治疗线数的增加，HRQoL 显著下降。处于首次无治疗间期的患者评分相对较高。在后续线治疗中，正在接受积极治疗的患者比治疗结束的患者评分更好。EORTC QLQ-C30 全球健康状况评分较高与治疗反应良好、不良事件少、治疗持续时间长有关，且强烈受东部肿瘤协作组表现状态的影响。全球健康状况评分与 QLQ-MY20 的 4 个项目相关性良好（未来展望，0.46；身体形象，0.41；疾病症状，-0.57；治疗副作用，-0.53）。
MM 的有效治疗选择可以通过影响治疗反应水平和延缓疾病进展来帮助维持 HRQoL。
